Loading…

Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?

Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria,...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-03, Vol.23 (7), p.3648
Main Authors: Grabowski, Łukasz, Gaffke, Lidia, Pierzynowska, Karolina, Cyske, Zuzanna, Choszcz, Marta, Węgrzyn, Grzegorz, Węgrzyn, Alicja
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143
cites cdi_FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143
container_end_page
container_issue 7
container_start_page 3648
container_title International journal of molecular sciences
container_volume 23
creator Grabowski, Łukasz
Gaffke, Lidia
Pierzynowska, Karolina
Cyske, Zuzanna
Choszcz, Marta
Węgrzyn, Grzegorz
Węgrzyn, Alicja
description Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria, mainly due to the inhibition of bacterial gyrase and topoisomerase IV enzymatic actions. The high efficacy of this molecule has been demonstrated in the treatment of various animals on farms and other locations. However, the use of enrofloxacin causes severe adverse effects, including skeletal, reproductive, immune, and digestive disorders. In this review article, we present in detail and discuss the advantageous and disadvantageous properties of enrofloxacin, showing the benefits and risks of the use of this compound in veterinary medicine. Animal health and the environmental effects of this stable antibiotic (with half-life as long as 3-9 years in various natural environments) are analyzed, as are the interesting properties of this molecule that are expressed when present in complexes with metals. Recommendations for further research on enrofloxacin are also proposed.
doi_str_mv 10.3390/ijms23073648
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5f73016c9cf5457bb4d92d4e9a5c99b9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5f73016c9cf5457bb4d92d4e9a5c99b9</doaj_id><sourcerecordid>2649589487</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143</originalsourceid><addsrcrecordid>eNpdkk1vEzEQhleIipbCjTOyxKUHtnj9sWtfQCVKaUQkJFTOlu21EwfHDrYXtf8ek5Qq5eTRzKNHfkfTNG86eIkxhx_cZpsRhgPuCXvWnHUEoRbCfnh-VJ82L3PeQIgwovxFc4opgRzC4azZzUOK1sc7qV1ob9cGfJ_K2pucwVfnvUkgWjCffsp0H4vTYGa8zyAmUCq6lLmAm7gzwIV949qt1gXIlXShTj5LXUxy0oNFsEYXF0P-9Ko5sdJn8_rhPW9-XM9vZzft8tuXxexq2WqKutIqRpUyeoSYDlpqNXKuiYRGUYSkIYT1tIcca6yJtUxhgqgdoSZUYsbGjuDzZnHwjlFuxC65bY0gonRi34hpJWSqibwR1A4Ydr3m2lJCB6XIyNFIDJdUc654dX08uHaT2ppRm1CS9E-kTyfBrcUq_haMc0ZJXwUXD4IUf00mF7F1WddVymDilAXqCaeMEzZU9N1_6CZOKdRV7SnYMdp3lXp_oHSKOSdjHz_TQfH3LMTxWVT87XGAR_jfHeA_i-i0aw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649018561</pqid></control><display><type>article</type><title>Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?</title><source>Open Access: PubMed Central</source><source>Publicly Available Content (ProQuest)</source><creator>Grabowski, Łukasz ; Gaffke, Lidia ; Pierzynowska, Karolina ; Cyske, Zuzanna ; Choszcz, Marta ; Węgrzyn, Grzegorz ; Węgrzyn, Alicja</creator><creatorcontrib>Grabowski, Łukasz ; Gaffke, Lidia ; Pierzynowska, Karolina ; Cyske, Zuzanna ; Choszcz, Marta ; Węgrzyn, Grzegorz ; Węgrzyn, Alicja</creatorcontrib><description>Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria, mainly due to the inhibition of bacterial gyrase and topoisomerase IV enzymatic actions. The high efficacy of this molecule has been demonstrated in the treatment of various animals on farms and other locations. However, the use of enrofloxacin causes severe adverse effects, including skeletal, reproductive, immune, and digestive disorders. In this review article, we present in detail and discuss the advantageous and disadvantageous properties of enrofloxacin, showing the benefits and risks of the use of this compound in veterinary medicine. Animal health and the environmental effects of this stable antibiotic (with half-life as long as 3-9 years in various natural environments) are analyzed, as are the interesting properties of this molecule that are expressed when present in complexes with metals. Recommendations for further research on enrofloxacin are also proposed.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms23073648</identifier><identifier>PMID: 35409007</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acids ; adverse effects ; Animal health ; Animals ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; antibiotic ; Antibiotics ; Antiinfectives and antibacterials ; Bacteria ; Bacterial infections ; Bacterial Infections - drug therapy ; Bacterial Infections - veterinary ; Bioavailability ; Caretta caretta ; Chelonia mydas ; DNA topoisomerase IV ; efficacy ; Enrofloxacin ; Enrofloxacin - pharmacology ; Enrofloxacin - therapeutic use ; Environmental effects ; Enzymes ; Eukaryotic Cells ; Fluoroquinolones ; Fluoroquinolones - pharmacology ; Fluoroquinolones - therapeutic use ; Gene expression ; Gram-Negative Bacteria ; Gram-Positive Bacteria ; Metabolism ; Metabolites ; Metals ; Oral administration ; Pharmacokinetics ; Polyvinyl alcohol ; Review ; safety ; Streptococcus infections ; toxicity ; Veterinary medicine</subject><ispartof>International journal of molecular sciences, 2022-03, Vol.23 (7), p.3648</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143</citedby><cites>FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143</cites><orcidid>0000-0003-4042-7466 ; 0000-0003-3746-8726 ; 0000-0002-3073-2814 ; 0000-0002-0820-7204 ; 0000-0003-3634-6567</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2649018561/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2649018561?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35409007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grabowski, Łukasz</creatorcontrib><creatorcontrib>Gaffke, Lidia</creatorcontrib><creatorcontrib>Pierzynowska, Karolina</creatorcontrib><creatorcontrib>Cyske, Zuzanna</creatorcontrib><creatorcontrib>Choszcz, Marta</creatorcontrib><creatorcontrib>Węgrzyn, Grzegorz</creatorcontrib><creatorcontrib>Węgrzyn, Alicja</creatorcontrib><title>Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria, mainly due to the inhibition of bacterial gyrase and topoisomerase IV enzymatic actions. The high efficacy of this molecule has been demonstrated in the treatment of various animals on farms and other locations. However, the use of enrofloxacin causes severe adverse effects, including skeletal, reproductive, immune, and digestive disorders. In this review article, we present in detail and discuss the advantageous and disadvantageous properties of enrofloxacin, showing the benefits and risks of the use of this compound in veterinary medicine. Animal health and the environmental effects of this stable antibiotic (with half-life as long as 3-9 years in various natural environments) are analyzed, as are the interesting properties of this molecule that are expressed when present in complexes with metals. Recommendations for further research on enrofloxacin are also proposed.</description><subject>Acids</subject><subject>adverse effects</subject><subject>Animal health</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>antibiotic</subject><subject>Antibiotics</subject><subject>Antiinfectives and antibacterials</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - veterinary</subject><subject>Bioavailability</subject><subject>Caretta caretta</subject><subject>Chelonia mydas</subject><subject>DNA topoisomerase IV</subject><subject>efficacy</subject><subject>Enrofloxacin</subject><subject>Enrofloxacin - pharmacology</subject><subject>Enrofloxacin - therapeutic use</subject><subject>Environmental effects</subject><subject>Enzymes</subject><subject>Eukaryotic Cells</subject><subject>Fluoroquinolones</subject><subject>Fluoroquinolones - pharmacology</subject><subject>Fluoroquinolones - therapeutic use</subject><subject>Gene expression</subject><subject>Gram-Negative Bacteria</subject><subject>Gram-Positive Bacteria</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metals</subject><subject>Oral administration</subject><subject>Pharmacokinetics</subject><subject>Polyvinyl alcohol</subject><subject>Review</subject><subject>safety</subject><subject>Streptococcus infections</subject><subject>toxicity</subject><subject>Veterinary medicine</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1vEzEQhleIipbCjTOyxKUHtnj9sWtfQCVKaUQkJFTOlu21EwfHDrYXtf8ek5Qq5eTRzKNHfkfTNG86eIkxhx_cZpsRhgPuCXvWnHUEoRbCfnh-VJ82L3PeQIgwovxFc4opgRzC4azZzUOK1sc7qV1ob9cGfJ_K2pucwVfnvUkgWjCffsp0H4vTYGa8zyAmUCq6lLmAm7gzwIV949qt1gXIlXShTj5LXUxy0oNFsEYXF0P-9Ko5sdJn8_rhPW9-XM9vZzft8tuXxexq2WqKutIqRpUyeoSYDlpqNXKuiYRGUYSkIYT1tIcca6yJtUxhgqgdoSZUYsbGjuDzZnHwjlFuxC65bY0gonRi34hpJWSqibwR1A4Ydr3m2lJCB6XIyNFIDJdUc654dX08uHaT2ppRm1CS9E-kTyfBrcUq_haMc0ZJXwUXD4IUf00mF7F1WddVymDilAXqCaeMEzZU9N1_6CZOKdRV7SnYMdp3lXp_oHSKOSdjHz_TQfH3LMTxWVT87XGAR_jfHeA_i-i0aw</recordid><startdate>20220326</startdate><enddate>20220326</enddate><creator>Grabowski, Łukasz</creator><creator>Gaffke, Lidia</creator><creator>Pierzynowska, Karolina</creator><creator>Cyske, Zuzanna</creator><creator>Choszcz, Marta</creator><creator>Węgrzyn, Grzegorz</creator><creator>Węgrzyn, Alicja</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4042-7466</orcidid><orcidid>https://orcid.org/0000-0003-3746-8726</orcidid><orcidid>https://orcid.org/0000-0002-3073-2814</orcidid><orcidid>https://orcid.org/0000-0002-0820-7204</orcidid><orcidid>https://orcid.org/0000-0003-3634-6567</orcidid></search><sort><creationdate>20220326</creationdate><title>Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?</title><author>Grabowski, Łukasz ; Gaffke, Lidia ; Pierzynowska, Karolina ; Cyske, Zuzanna ; Choszcz, Marta ; Węgrzyn, Grzegorz ; Węgrzyn, Alicja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acids</topic><topic>adverse effects</topic><topic>Animal health</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>antibiotic</topic><topic>Antibiotics</topic><topic>Antiinfectives and antibacterials</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - veterinary</topic><topic>Bioavailability</topic><topic>Caretta caretta</topic><topic>Chelonia mydas</topic><topic>DNA topoisomerase IV</topic><topic>efficacy</topic><topic>Enrofloxacin</topic><topic>Enrofloxacin - pharmacology</topic><topic>Enrofloxacin - therapeutic use</topic><topic>Environmental effects</topic><topic>Enzymes</topic><topic>Eukaryotic Cells</topic><topic>Fluoroquinolones</topic><topic>Fluoroquinolones - pharmacology</topic><topic>Fluoroquinolones - therapeutic use</topic><topic>Gene expression</topic><topic>Gram-Negative Bacteria</topic><topic>Gram-Positive Bacteria</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metals</topic><topic>Oral administration</topic><topic>Pharmacokinetics</topic><topic>Polyvinyl alcohol</topic><topic>Review</topic><topic>safety</topic><topic>Streptococcus infections</topic><topic>toxicity</topic><topic>Veterinary medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grabowski, Łukasz</creatorcontrib><creatorcontrib>Gaffke, Lidia</creatorcontrib><creatorcontrib>Pierzynowska, Karolina</creatorcontrib><creatorcontrib>Cyske, Zuzanna</creatorcontrib><creatorcontrib>Choszcz, Marta</creatorcontrib><creatorcontrib>Węgrzyn, Grzegorz</creatorcontrib><creatorcontrib>Węgrzyn, Alicja</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grabowski, Łukasz</au><au>Gaffke, Lidia</au><au>Pierzynowska, Karolina</au><au>Cyske, Zuzanna</au><au>Choszcz, Marta</au><au>Węgrzyn, Grzegorz</au><au>Węgrzyn, Alicja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2022-03-26</date><risdate>2022</risdate><volume>23</volume><issue>7</issue><spage>3648</spage><pages>3648-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria, mainly due to the inhibition of bacterial gyrase and topoisomerase IV enzymatic actions. The high efficacy of this molecule has been demonstrated in the treatment of various animals on farms and other locations. However, the use of enrofloxacin causes severe adverse effects, including skeletal, reproductive, immune, and digestive disorders. In this review article, we present in detail and discuss the advantageous and disadvantageous properties of enrofloxacin, showing the benefits and risks of the use of this compound in veterinary medicine. Animal health and the environmental effects of this stable antibiotic (with half-life as long as 3-9 years in various natural environments) are analyzed, as are the interesting properties of this molecule that are expressed when present in complexes with metals. Recommendations for further research on enrofloxacin are also proposed.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35409007</pmid><doi>10.3390/ijms23073648</doi><orcidid>https://orcid.org/0000-0003-4042-7466</orcidid><orcidid>https://orcid.org/0000-0003-3746-8726</orcidid><orcidid>https://orcid.org/0000-0002-3073-2814</orcidid><orcidid>https://orcid.org/0000-0002-0820-7204</orcidid><orcidid>https://orcid.org/0000-0003-3634-6567</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2022-03, Vol.23 (7), p.3648
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_5f73016c9cf5457bb4d92d4e9a5c99b9
source Open Access: PubMed Central; Publicly Available Content (ProQuest)
subjects Acids
adverse effects
Animal health
Animals
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antibacterial agents
antibiotic
Antibiotics
Antiinfectives and antibacterials
Bacteria
Bacterial infections
Bacterial Infections - drug therapy
Bacterial Infections - veterinary
Bioavailability
Caretta caretta
Chelonia mydas
DNA topoisomerase IV
efficacy
Enrofloxacin
Enrofloxacin - pharmacology
Enrofloxacin - therapeutic use
Environmental effects
Enzymes
Eukaryotic Cells
Fluoroquinolones
Fluoroquinolones - pharmacology
Fluoroquinolones - therapeutic use
Gene expression
Gram-Negative Bacteria
Gram-Positive Bacteria
Metabolism
Metabolites
Metals
Oral administration
Pharmacokinetics
Polyvinyl alcohol
Review
safety
Streptococcus infections
toxicity
Veterinary medicine
title Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A17%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enrofloxacin-The%20Ruthless%20Killer%20of%20Eukaryotic%20Cells%20or%20the%20Last%20Hope%20in%20the%20Fight%20against%20Bacterial%20Infections?&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Grabowski,%20%C5%81ukasz&rft.date=2022-03-26&rft.volume=23&rft.issue=7&rft.spage=3648&rft.pages=3648-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms23073648&rft_dat=%3Cproquest_doaj_%3E2649589487%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c521t-b85bbecd0357cacbd99c4a0eb522ae448656093c3c4ff8b3425fd0c45a388d143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2649018561&rft_id=info:pmid/35409007&rfr_iscdi=true